Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Trastuzumab (Herceptin™) is a humanized anti-ErbB2 monoclonal antibody that has been approved for the treatment in the adjuvant and the metastatic setting of breast cancer patients that either overexpress ErbB2, or demonstrate ErbB2 gene amplification. An important serious adverse event associated with trastuzumab is the reduction of left heart ejection fraction resulting to congestive heart failure. The role of pharmacogenomics in breast cancer targeted treatment has been well recognized. However, data on the role of pharmacogenomics on the efficacy and safety of trastuzumab are still scarce.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi